United States· US:85437-093_42776e01-ac39-5aa4-e063-6294a90a99e9
Auranofin
A auranofin product containing auranofin, registered in United States by Coral Way Pharma, LLC. The same ATC class is registered in 5 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Auranofin is registered in 5 of 19 countries.
Countries holding a registration under ATC M01CB03 (auranofin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 3 of them publish a price we can compare per daily dose
Auranofin · ATC M01CB03
5 / 19 countries
- Canada
- Finlandprice
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- AURANOFIN
- Manufacturer
- Coral Way Pharma, LLC
- Country
- United States (US)
- ATC code
- M01CB03
- ATC class
- Auranofin
- Defined daily dose
- 6 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11854370930660 CAPSULE in 1 BOTTLE (85437-093-06)
- ndc1185437-093-06
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
113 interactions on record for auranofin.
Graded by severity as the source publishes them — 16 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Auranofin · interactions on record
113 records
- 16 severe
- 69 moderate
- 28 info
Most severe, free to view
- CladribineL01BB04severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- CladribineL04AA40severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Auranofin in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4419b610-db6c-4cc6-96bd-9cddd6e4db43 GET /v1/drugs/4419b610-db6c-4cc6-96bd-9cddd6e4db43?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "3",
"substance": "AURANOFIN",
"productndc": "85437-093",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA018689",
"marketing_category": "NDA AUTHORIZED GENERIC"
}See everything about auranofin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.